The KD Pharma Group has acquired the manufacturing assets of the former Rohner AG. The assets give KD Pharma access to new complementary technologies that will allow the company to further expand its pharmaceutical CDMO business. In addition, KD Pharma has strengthened its CDMO team by hiring several key personnel from the former Rohner team.
 
“KD Pharma has all the technology, capacity, and people to become an even larger player in the CDMO market,” said Oscar Groet, CEO of the KD Pharma Group. “Rohner was known for its unique chemical processes and technological capabilities, enabling it to manufacture difficult, multi-step pharmaceutical intermediates and APIs. This is a natural fit with our strategy to create health solutions and provide value to customers by utilizing a unique toolbox of technologies.”
 
The KD Pharma Group has an existing CDMO site in the UK, as well as a contract softgel manufacturing site in the U.S. and omega-3 manufacturing sites in Norway and Germany.